Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 3.54
CMXI's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 3.54 )
CMXI' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 3.54

Equity to Asset 0.50
CMXI's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 0.50 )
CMXI' s 10-Year Equity to Asset Range
Min: -8.63   Max: 0.86
Current: 0.5

-8.63
0.86
F-Score: 4
Z-Score: -2.58
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -156.38
CMXI's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -156.38 )
CMXI' s 10-Year Operating margin (%) Range
Min: -68755.56   Max: -48.49
Current: -156.38

-68755.56
-48.49
Net-margin (%) -174.99
CMXI's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -174.99 )
CMXI' s 10-Year Net-margin (%) Range
Min: -68777.78   Max: -48.45
Current: -174.99

-68777.78
-48.45
ROE (%) -76.95
CMXI's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -76.95 )
CMXI' s 10-Year ROE (%) Range
Min: -3292.57   Max: -26.55
Current: -76.95

-3292.57
-26.55
ROA (%) -43.78
CMXI's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -43.78 )
CMXI' s 10-Year ROA (%) Range
Min: -2226.62   Max: -22.11
Current: -43.78

-2226.62
-22.11
ROC (Joel Greenblatt) (%) -1968.99
CMXI's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -1968.99 )
CMXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34658.33   Max: -358.94
Current: -1968.99

-34658.33
-358.94
Revenue Growth (%) 3.20
CMXI's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 3.20 )
CMXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 44.2
Current: 3.2

0
44.2
EBITDA Growth (%) 4.60
CMXI's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 4.60 )
CMXI' s 10-Year EBITDA Growth (%) Range
Min: -57.5   Max: 11.9
Current: 4.6

-57.5
11.9
EPS Growth (%) -4.60
CMXI's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -4.60 )
CMXI' s 10-Year EPS Growth (%) Range
Min: -51.6   Max: 38.7
Current: -4.6

-51.6
38.7
» CMXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CMXI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
CMXI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 1.70 )
CMXI' s 10-Year P/B Range
Min: 1.16   Max: 89.1
Current: 1.7

1.16
89.1
P/S 4.00
CMXI's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 4.00 )
CMXI' s 10-Year P/S Range
Min: 2.42   Max: 134.2
Current: 4

2.42
134.2
EV-to-EBIT -2.37
CMXI's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -2.37 )
CMXI' s 10-Year EV-to-EBIT Range
Min: 205.8   Max: 284.4
Current: -2.37

205.8
284.4
Current Ratio 1.57
CMXI's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 1.57 )
CMXI' s 10-Year Current Ratio Range
Min: 0.11   Max: 15.38
Current: 1.57

0.11
15.38
Quick Ratio 1.48
CMXI's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 1.48 )
CMXI' s 10-Year Quick Ratio Range
Min: 0.11   Max: 15.38
Current: 1.48

0.11
15.38

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
CMXI's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: 0.40 )
CMXI' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 260.42
Current: 0.4

0.26
260.42
Forward Rate of Return (Yacktman) -23.68
CMXI's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CMXI: -23.68 )
CMXI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.2   Max: -20.7
Current: -23.68

-23.2
-20.7

Business Description

Industry: »
Compare: » details
Cytomedix, Inc. formerly Informatix Holdings, Inc. was incorporated in Delaware in 1998. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving Corporation was changed to Autologous Wound Therapy, Inc. In 2000, AWT changed its name to Cytomedix, Inc. Cytomedix, Inc. develops, sells, and licenses regenerative biological therapies intended to aid the human body in regenerating/healing itself, to primarily address the areas of wound care, infection control, and orthopedic surgery. The Company currently markets the AutoloGelTM System, as well as the Angel Whole Blood Separation System and activAT Autologous Thrombin Processing Kit ("activAT"), both of which were acquired from Sorin USA, Inc. ("Sorin") in April 2010. AutoloGelTM is a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGelTM System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGelTM System. Additionally, the Company has entered into an option agreement with a top 20 global pharmaceutical company granting the potential partner an exclusive option period through June 30, 2012 regarding license of the AutoloGelTM System. Angel and activAT are used primarily in surgical settings. Angel is used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma. ActivAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products. The Company is also pursuing opportunities for the application of AutoloGelTM and Angel into other markets such as hair transplantation, pain management, and sports medicine, as well as actively seeking complementary products for regenerative medicine markets. Cytomedix sells its products primarily to health care providers in the United States.
» More Articles for CMXI

Headlines

Articles On GuruFocus.com
Health Care Sector in an Upward Climb in June Jun 12 2014 
Large Insider buying Mar 01 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 

More From Other Websites
CYTOMEDIX INC Files SEC form 8-K/A, Change in Directors or Principal Officers Jul 18 2014
CYTOMEDIX COMPLETES THE SECOND TRANCHE OF THE $35 MILLION CONVERTIBLE DEBT FINANCING WITH DEERFIELD... Jul 08 2014
CYTOMEDIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 01 2014
Cytomedix Completes the Second Tranche of the $35 Million Convertible Debt Financing With Deerfield... Jun 26 2014
CYTOMEDIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Jun 13 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cytomedix,... Jun 03 2014
CYTOMEDIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... May 30 2014
CYTOMEDIX INC Financials May 23 2014
Why I'm Early, But Bullish On Cytomedix May 20 2014
Cytomedix's (CMXI) CEO Martin Rosendale On Q1 2014 Results - Earnings Call Transcript May 16 2014
CYTOMEDIX INC Files SEC form 10-Q, Quarterly Report May 15 2014
Cytomedix Reports 2014 First Quarter Financial Results May 15 2014
CYTOMEDIX INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Other Events May 08 2014
Cytomedix to Host First Quarter 2014 Financial Results Conference Call on Friday, May 16, 2014 May 08 2014
Cytomedix Announces Results of RECOVER-Stroke Phase 2 Study; Provides Update on R&D Reorganization... May 05 2014
CMXI: We Recommend Buying Cytomedix Post SAWC Apr 28 2014
CYTOMEDIX INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 11 2014
Time To Back Up The Truck On Cytomedix? Apr 04 2014
Cytomedix's CEO Discusses Q4 2013 Results - Earnings Call Transcript Apr 01 2014
CYTOMEDIX INC Files SEC form 10-K, Annual Report Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide